Physician profile
Scott Drew
NPI 1952796047
$7,459.51
in general payments reported to CMS, 2019-2025
9 companies · $4,267 in 2025
The $4,267 reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.92 · 2020: $333 · 2021: $268 · 2022: $158 · 2023: $285 · 2024: $2,111 · 2025: $4,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,700 · Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,700.00 |
| Food and Beverage | $962.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,564.69 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $2,002.25 | 2024-2025 | Bimzelx |
| Journey Medical Corporation | $286.88 | 2020 | |
| Galderma Laboratories, L.P. | $257.83 | 2019-2024 | |
| Abbvie INC. | $102.17 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $81.70 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $69.90 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $67.88 | 2023-2024 | Zoryve |
| Janssen Biotech, INC. | $26.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.